Topical Avastin for Treatment of Corneal Neovascularization

Status Completed

Clinical Trial Summary

The purpose of this study is to determine the effectiveness and safety of Topical Bevacizumab (Avastin) for treatment of corneal neovascularization.

Clinical Trial Description

Primary outcomes measures included neovascular area (NA), defined as the area of the corneal vessels themselves; vessel caliber (VC), defined as the mean diameter of the corneal vessels; and invasion area (IA), defined as the fraction of the total cornea into which the vessels extend. The occurrence of ocular and systemic adverse events was closely monitored throughout the course of the study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00559936
Study type	Interventional
Source	Massachusetts Eye and Ear Infirmary
Contact
Status	Completed
Phase	Phase 1
Start date	February 2007
Completion date	October 2010

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00555594` - Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization	Phase 2/Phase 3
Completed	`NCT00004430` - Randomized Study of Photodynamic Therapy Using Dihematoporphyrin in Patients With Corneal Neovascularization	N/A
Completed	`NCT00769145` - Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery	Phase 1
Completed	`NCT01257750` - Treatment of Corneal Neovascularization With Topical Pazopanib	Phase 1/Phase 2
Recruiting	`NCT04787471` - Corneal Crosslinking for Treatment of Corneal Neovascularization	Phase 2/Phase 3
Not yet recruiting	`NCT06412718` - Validation of Human Drugs Target of Repurposed Drugs and Novel Therapies
Active, not recruiting	`NCT00992849` - Bevacizumab for the Treatment of Corneal Neovascularization	Phase 2
Withdrawn	`NCT00515684` - Corneal Thinning During Topical Bevacizumab Therapy	N/A
Terminated	`NCT02797704` - Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization	Phase 1/Phase 2
Terminated	`NCT01868360` - Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea	Phase 1
Withdrawn	`NCT02042027` - Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions	Phase 1
Recruiting	`NCT04215393` - An Exploratory Clinical Trial Evaluating the Tolerability and Efficacy of KH906 in Patients With Corneal Neovascularization	Phase 1
Completed	`NCT00797303` - The Effect of Bevacizumab on Corneal Neovascularization	Phase 4
Recruiting	`NCT05659940` - Correlation Between a Novel Subset of Neutrophil and Corneal Neovascularization.
Completed	`NCT01072357` - Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival	Phase 1/Phase 2
Recruiting	`NCT04620109` - Clinical Evaluation of Safety and Tolerability of KDR2-2 Eye Drops in Healthy Volunteers With Pharmacokinetic Assessment	Phase 1
Completed	`NCT00512876` - Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization	N/A
Recruiting	`NCT05011916` - The Safety and Efficacy of KDR2-2 Suspension Eye Drops in the Treatment of Corneal Neovascularization	Phase 1/Phase 2
Completed	`NCT01996826` - A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival	Phase 1/Phase 2
Terminated	`NCT00915590` - Topical IL-1-Ra for Treatment of Corneal Neovascularization	Phase 1/Phase 2